Multiple new COVID-19 variants are circulating in early 2026, with XFG (nicknamed “Stratus”) dominating United States infections at up to 85% of new cases in some regions. Alongside XFG, variants including BA.3.2 (“Cicada”) and NB.1.8.1 (“Nimbus”) are spreading across multiple continents, prompting renewed surveillance from the CDC and World Health Organization.
These strains descend from Omicron lineages such as JN.1 and LP.8.1, continuing the pattern of viral evolution characterized by immune escape mutations. While hospitalization rates remain low nationally, the genetic distance of emerging variants like BA.3.2 raises questions about vaccine durability and symptom profiles.
Understanding the distinct characteristics of these strains—ranging from NB.1.8.1’s severe sore throat signature to BA.3.2’s extensive spike protein mutations—provides clarity for individuals navigating respiratory illness risks in 2026.
What Is the New COVID Strain?
Health authorities are currently tracking several distinct lineages simultaneously. XFG represents the dominant strain in the United States, accounting for roughly 23% to 85% of new infections depending on regional surveillance data. Meanwhile, BA.3.2 has emerged as a variant of concern due to its significant genetic divergence from existing vaccine targets, first identified in South Africa in November 2024. NB.1.8.1, commonly called “Nimbus,” originated as a hybrid of JN.1 and XBB lineages and was first detected in China in January 2025.
Primary Lineages & Mutations
BA.3.2: 70-75 spike protein substitutions/deletions
NB.1.8.1: JN.1/XBB hybrid via XDV.1.5.1
XFG: Sublineages XFG.1.1, XFG.14.1 monitored
Contagiousness Level
High: NB.1.8.1 shows rapid spread capability
XFG: Up to 85% of new US infections
BA.3.2: Immune escape potential confirmed
Severity vs Prior Strains
No increase in inherent severity detected
Hospitalizations remain very low per CDC
Symptoms range mild to severe
Vaccine Match Status
Reduced protection possible against BA.3.2
Current vaccines target JN.1/LP.8.1
No updated vaccine specifics for 2026
Key Insights on Emerging Variants
- XFG dominance: Currently accounts for the majority share of US infections, with some regional estimates reaching 85%.
- Genetic divergence: BA.3.2 carries 70-75 mutations in its spike protein compared to current vaccine antigens, marking it as a distinct lineage.
- Distinctive symptoms: NB.1.8.1 (Nimbus) is specifically associated with unusually severe throat pain unlike previous variants.
- Global spread: As of February 11, 2026, BA.3.2 has been confirmed in 23 countries and 25 US states via wastewater surveillance.
- Testing continuity: Standard PCR and rapid antigen tests remain effective for detecting all circulating variants.
- Low hospitalization impact: Despite increased transmissibility, national hospitalization rates remain minimal.
| Attribute | BA.3.2 (“Cicada”) | NB.1.8.1 (“Nimbus”) | XFG (“Stratus”) |
|---|---|---|---|
| First Detection | November 2024, South Africa | January 2025, China | Monitored since 2025 |
| US Clinical Case | January 5, 2026 | Spreading nationwide | Dominant 2025-2026 |
| Prevalence | 30% in Denmark/Germany (Nov-Jan) | Worldwide spread | ~23-85% US cases |
| Key Mutation | 70-75 spike substitutions | JN.1/XBB hybrid | LP.8.1 descendant |
| Distinctive Symptom | Standard Omicron profile | Severe sharp throat pain | Standard Omicron profile |
| Immune Escape | Confirmed potential | High transmissibility | Under monitoring |
Symptoms of the New COVID Strain
Clinical presentations for BA.3.2 and XFG largely mirror previous Omicron infections, typically presenting with fever, cough, runny nose, and general fatigue. However, healthcare providers have noted specific variations in symptom intensity and onset between the circulating lineages.
The Nimbus Variant’s Distinctive Throat Pain
NB.1.8.1 has garnered attention for producing an unusually severe sore throat described by patients as sharp, stabbing, or knife-like, particularly painful when swallowing. Stony Brook Medicine and other clinical centers report this symptom as distinctive enough to differentiate Nimbus from typical seasonal respiratory infections. Accompanying symptoms include congestion, dry cough, headache, mild fever, and body aches.
Medical facilities report that loss of taste and smell occurs less frequently with NB.1.8.1 compared to earlier COVID-19 waves, making symptom-based diagnosis more challenging without laboratory confirmation.
General Symptom Overlap with Previous Omicron Strains
BA.3.2 and XFG typically present with the familiar constellation of upper respiratory symptoms: runny nose, sore throat (though generally less severe than Nimbus), cough, and fatigue. Healthline reports that symptom progression follows patterns similar to JN.1 descendants, usually beginning with nasal symptoms before progressing to throat irritation and cough.
Disappearing Hallmarks
Anosmia (loss of smell) and ageusia (loss of taste), once considered COVID-19 signatures, have become significantly less common across all current variants. Clinical surveillance indicates these neurological symptoms now appear in only a minority of cases, further blurring the distinction between COVID-19 and influenza or severe colds.
How Contagious and Severe Is the New COVID Strain?
Transmission Dynamics and Immune Escape
XFG demonstrates the highest prevalence, with surveillance data suggesting it drives the majority of new infections in the United States. NB.1.8.1 exhibits notably high transmissibility with documented rapid spread and recurrence rates in exposed populations. BA.3.2 presents a different challenge: its 70-75 spike protein mutations relative to current vaccine targets create confirmed immune escape potential, potentially reducing protection levels from both prior infection and vaccination.
BA.3.2’s extensive spike protein mutations may reduce protection conferred by current vaccines targeting JN.1/LP.8.1 antigens. Ongoing surveillance is required to determine exact efficacy impacts.
Severity Assessment
Despite increased transmissibility, no data indicates these variants cause more severe disease than previous Omicron strains for the general population. CDC data shows cases and hospitalizations remain very low nationally. Symptom intensity continues to range from mild to severe, with most individuals experiencing manageable upper respiratory illness.
High-Risk Populations
While severity remains generally low, vulnerable groups—including immunocompromised individuals, elderly patients, and those with underlying respiratory conditions—face elevated risks from any circulating respiratory virus. Priority Care Clinics notes that high transmission rates in community settings pose particular dangers for these populations despite the reduced individual severity of the strains.
Vaccine Effectiveness, Testing, and Protection Against the New Strain
Vaccine Match and Efficacy Concerns
Current COVID-19 vaccines target JN.1 and LP.8.1 antigens. BA.3.2’s substantial genetic distance—marked by 70-75 spike protein substitutions—suggests potential for reduced neutralizing antibody protection. Health authorities emphasize that while protection against severe disease likely persists, the precise efficacy rates against symptomatic BA.3.2 infection remain under investigation. No updated vaccine formulations specifically targeting 2026 strains have been announced.
Diagnostic Testing Capabilities
Standard PCR and rapid antigen tests detect all currently circulating variants including BA.3.2, NB.1.8.1, and XFG. However, MedPark Hospital warns that symptom overlap with influenza and common colds complicates clinical differentiation without laboratory confirmation. Genomic surveillance through wastewater monitoring and traveler screening remains the primary method for tracking variant distribution, with CDC and WHO maintaining active surveillance networks.
Health agencies utilize wastewater surveillance, traveler screening, and genomic sequencing to track variant spread. BA.3.2 has been detected in 25 US states through wastewater monitoring alone.
Protection Strategies
CDC and WHO guidance emphasizes continued genomic surveillance rather than new specific behavioral restrictions, noting the currently low national disease burden. Standard respiratory hygiene—ventilation, hand hygiene, and masking during active illness—remains applicable. Those seeking to optimize their health infrastructure while managing seasonal illness risks might consider ergonomic home office adjustments such as a Stand Up Desk – Best Lab-Tested Picks for 2025 to maintain mobility during recovery periods.
When Did the New COVID Strain First Emerge?
- : BA.3.2 first identified in South Africa.
- : NB.1.8.1 (Nimbus) first detected in China as a JN.1/XBB hybrid.
- : First US detection of BA.3.2 via CDC traveler surveillance from the Netherlands.
- : BA.3.2 detections begin rising across European surveillance networks.
- : BA.3.2 reaches 30% prevalence in Denmark, Germany, and the Netherlands.
- : First clinical US case of BA.3.2 confirmed.
- : BA.3.2 confirmed in 23 countries and 25 US states via wastewater surveillance.
What Is Certain vs. Uncertain About the New Strains?
| Established Facts | Information Remaining Unclear |
|---|---|
| XFG is dominant in the US, comprising up to 85% of infections in some reports | Specific incubation periods for BA.3.2 and NB.1.8.1 remain unestablished |
| BA.3.2 possesses 70-75 spike protein mutations creating immune escape potential | Exact duration of vaccine-induced immunity against new strains |
| NB.1.8.1 causes distinctive severe sore throat symptoms | Precise vaccine efficacy percentages against symptomatic BA.3.2 infection |
| No increased severity over prior Omicron variants for general population | Timeline for availability of updated vaccine formulations targeting 2026 strains |
| Standard tests effectively detect all circulating variants | Long-term evolutionary trajectory of JN.1 descendants |
| Loss of taste/smell occurs less frequently than in earlier pandemic waves | Potential for seasonal resurgence patterns specific to these lineages |
How Do These Strains Fit Into the COVID-19 Landscape?
The emergence of BA.3.2, NB.1.8.1, and XFG represents continued Omicron evolution rather than a shift to an entirely new viral family. All three descend from JN.1 or LP.8.1 lineages, maintaining the immune escape characteristics that define recent COVID-19 epidemiology while potentially sacrificing some of the severe lung tropism seen in Delta-era variants.
This evolutionary pattern suggests SARS-CoV-2 has entered a phase of immune system adaptation rather than virulence maximization. The virus appears to be optimizing for transmission through populations with existing immunity from prior infection or vaccination—a trajectory consistent with endemic pathogen behavior. For individuals managing long-term health during this transition phase, maintaining wellness routines including regular movement and recovery protocols becomes essential. Those interested in complementary wellness approaches might review Infrared Sauna Benefits – What Science Says in 2025 for evidence-based recovery methods.
Global health agencies continue monitoring these lineages through genomic surveillance networks, maintaining readiness should any variant demonstrate significant phenotype shifts toward increased severity or vaccine resistance.
What Are Experts Saying About the New COVID Strain?
BA.3.2 features 70-75 substitutions/deletions in its spike protein relative to JN.1/LP.8.1 (vaccine antigens), marking it as a new lineage distinct from US-circulating JN.1 descendants.
Center for Infectious Disease Research and Policy, University of Minnesota
Experts monitor for public health impact while emphasizing that current hospitalization rates remain very low nationally.
CIDRAP, University of Minnesota
Additional surveillance data provided by Nebraska Medicine and the Stony Brook Medicine clinical teams continues to inform public health guidance regarding symptom recognition and testing protocols.
What Should You Remember About the New COVID Strain?
Multiple Omicron-descendant variants currently circulate in early 2026, with XFG dominating US infections while BA.3.2 and NB.1.8.1 spread globally. BA.3.2’s extensive mutations pose potential immune escape challenges, and NB.1.8.1 distinguishes itself through severe sore throat symptoms. Severity remains comparable to previous Omicron waves, hospitalizations stay low, and standard tests remain effective. Continued surveillance guides public health response as agencies monitor for phenotype changes. Maintaining general health practices, including consideration of ergonomic solutions like those found in the Stand Up Desk – Best Lab-Tested Picks for 2025 guide, supports overall wellness during ongoing viral circulation.
Frequently Asked Questions
Is the new COVID strain causing more hospitalizations?
No. Current CDC data indicates hospitalization rates remain very low in the United States, with no evidence that BA.3.2, NB.1.8.1, or XFG cause more severe illness than previous Omicron variants for the general population.
What specific mutations does BA.3.2 carry?
BA.3.2 features 70 to 75 substitutions or deletions in its spike protein relative to JN.1 and LP.8.1 antigens. It has evolved into sublineages BA.3.2.1 and BA.3.2.2, continuing to diverge from vaccine targets.
How does NB.1.8.1 differ from XFG?
NB.1.8.1 (Nimbus) originated as a hybrid of JN.1 and XBB lineages, while XFG descends from LP.8.1. Nimbus is noted for high transmissibility and distinctive severe sore throat symptoms, whereas XFG currently dominates US case counts without that specific symptom signature.
Can standard rapid tests detect these new variants?
Yes. Standard PCR and rapid antigen tests detect BA.3.2, NB.1.8.1, and XFG. However, they cannot identify which specific variant is present; genomic sequencing is required for lineage determination.
Has the incubation period changed with these variants?
Specific incubation period data for BA.3.2 and NB.1.8.1 remains unestablished in current research. General estimates follow previous Omicron timelines of 2-14 days, though precise studies are pending.
Should vulnerable groups take additional precautions?
Yes. While severity is generally low, high transmissibility rates pose risks to elderly, immunocompromised, and respiratory-compromised individuals. Standard protective measures including ventilation, masking in high-risk settings, and prompt testing when symptomatic remain recommended.
Related stories
Liam O'Brien covers Australian politics and public affairs for Australian News Desk.